<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212328</url>
  </required_header>
  <id_info>
    <org_study_id>UTRN 022342347-29072010248</org_study_id>
    <nct_id>NCT01212328</nct_id>
  </id_info>
  <brief_title>A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia</brief_title>
  <acronym>CARRS</acronym>
  <official_title>Developing and Testing Integrated, Multi-factorial Cardiovascular Disease Risk Reduction Strategies in South Asia (CARRS Translation Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Public Health Foundation of India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>United Health Group, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Madras Diabetes Research Foundation, Chennai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Public Health Foundation of India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Cardiovascular diseases (CVD) are currently the leading cause of death globally&#xD;
      and Asian Indians will account for between 40-60% of the global CVD burden within the next&#xD;
      10-15 years. Risk factor control and preventive care are effective in reducing CVD events and&#xD;
      mortality. The greatest gains in CVD prevention have been seen when early and target-driven&#xD;
      interventions address multiple risk factors together. However, achieving control of even&#xD;
      individual risk factors (blood glucose, blood pressure, or blood lipid targets) is poor,&#xD;
      globally. Quality improvement schemes, like the proposed intervention, have shown promise in&#xD;
      high-income countries, but are untested in South Asia; a region with a population at&#xD;
      extraordinarily high CVD risk.&#xD;
&#xD;
      Objective: To test whether a clinic-based case management intervention (consisting of&#xD;
      guidelines based treatment, care coordinator assistance and decision support software) to&#xD;
      reduce cardiovascular disease (CVD) risk among Type 2 diabetes patients in South Asia, is&#xD;
      more effective and sustainable compared to existing care.&#xD;
&#xD;
      Trial subjects and methods: The study will involve a total of 1120 patients attending 8&#xD;
      established out-patient clinics in South Asia (140 patients at each clinic). Patients&#xD;
      enrolled in the trial will be randomly assigned to either the control (existing care) or the&#xD;
      intervention group and will be followed up for an average of 30 months. The total trial&#xD;
      duration is about 3.5 years, from mid-August 2010 to December 31, 2013.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple CVD risk factor control targets</measure>
    <time_frame>42 months after randomization</time_frame>
    <description>The study has one primary outcome of interest, multiple CVD risk factor control targets: at least two targets including Hemoglobin A1c (HbA1c) &lt; 7.0% and at least one of: Blood Pressure (BP) &lt; 130/80 mmHg or Low Density Lipoprotein (LDL)-cholesterol &lt; 100 mg/dl (LDL cholesterol &lt; 70 mg/dl for those with history of CVD event)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single risk factor control of at least one target either HbA1c or blood pressure or LDL-Cholesterol</measure>
    <time_frame>42 months after randomization</time_frame>
    <description>Single risk factor control&#xD;
absolute 10% point greater proportion of participants in the intervention group achieving good glycemic control (HbA1c &lt; 7%)&#xD;
systolic BP &lt; 130 and diastolic BP &lt; 80 mmHg&#xD;
LDL-cholesterol &lt; 100 mg/dl, &lt; 70 mg/dl for those with history of CVD event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cost effectiveness analysis of the intervention compared to the usual care.</measure>
    <time_frame>42 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>42 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prescriber and patient acceptability of the Digital Support software and care coordinator with management guidelines.</measure>
    <time_frame>42 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1120</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Hypertension</condition>
  <condition>Dyslipidaemia</condition>
  <arm_group>
    <arm_group_label>Care coordinator + Decision Support Software</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Care Coordinator + Decision Support Software</intervention_name>
    <description>Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)</description>
    <arm_group_label>Care coordinator + Decision Support Software</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 35 years and older&#xD;
&#xD;
          2. Confirmed diagnosis of diabetes based on documented evidence from oral glucose&#xD;
             tolerance test or two venous fasting blood sugar levels or known diabetes patient on&#xD;
             medication or insulin&#xD;
&#xD;
          3. Poor glycemic control (as evidenced by HbA1c &gt;=8.0%) and one or both of: dyslipidemia&#xD;
             [Low density Lipoprotein (LDL) &gt;=130 mg/dl] or systolic hypertension [Systolic Blood&#xD;
             Pressure (SBP) &gt;=140 mmHg], irrespective of lipid- or BP-lowering medication use,&#xD;
             respectively&#xD;
&#xD;
          4. Receiving diabetes care in the same clinic for at least 3 months OR even earlier if in&#xD;
             the investigator's assessment the patient is likely to follow-up regularly as required&#xD;
             by the protocol.&#xD;
&#xD;
          5. Willingness to consent to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals will be excluded from participation if any of the following are present during&#xD;
        screening:&#xD;
&#xD;
          1. Known type 1 diabetes mellitus&#xD;
&#xD;
          2. Diabetes secondary to chronic pancreatitis&#xD;
&#xD;
          3. Pregnant OR trying to become pregnant OR of child-bearing potential and not actively&#xD;
             practicing birth control (including natural methods)&#xD;
&#xD;
          4. Evidence of pre-existing well-controlled blood glucose, blood pressure or&#xD;
             LDL-cholesterol (as evidenced by HbA1c &lt; 7.0%, SBP &lt; 130 mmHg, LDL-cholesterol &lt; 100&#xD;
             mg/dl [LDL-cholesterol &lt; 70 mg/dl with history of CVD event]) obtained from screening&#xD;
             within a period not exceeding 28 days (4 weeks) prior to randomization&#xD;
&#xD;
          5. Documented cardiovascular event (coronary revascularization, stroke, MI, unstable&#xD;
             angina) in past 12 months&#xD;
&#xD;
          6. Current symptomatic Congestive Heart Failure (CHF) or New York Heart Association&#xD;
             (NYHA) Class 3 or 4 effort intolerance&#xD;
&#xD;
          7. Documented non-diabetic kidney disease OR pre-existing end -stage renal disease (on&#xD;
             renal replacement therapy [dialysis or transplant])&#xD;
&#xD;
          8. Transaminase &gt;3 times upper limit of normal OR active liver disease within past 2&#xD;
             years&#xD;
&#xD;
          9. Malignancy or life-threatening disease with death probable in 4 years&#xD;
&#xD;
         10. Any current medication (e.g. long-term steroids, protease inhibitors) that, in the&#xD;
             opinion of the site investigator, would interfere with participant's diabetic status&#xD;
             and follow-up&#xD;
&#xD;
         11. Any condition or circumstance that is unrelated to diabetes progression, that in the&#xD;
             opinion of the site investigator would interfere with the participant's diabetic&#xD;
             status and follow-up: including (but not limited to) other endocrinopathy [adrenal,&#xD;
             pituitary], Tuberculosis (TB) patient on treatment, psychiatric illness or cognitive&#xD;
             impairment, alcohol or drug abuse, history of organ transplant, Body Mass index (BMI)&#xD;
             &gt;= 45 kg/m2&#xD;
&#xD;
         12. On an investigational drug in the last 3 months&#xD;
&#xD;
         13. Currently participating in a clinical trial&#xD;
&#xD;
         14. No fixed address or contact details&#xD;
&#xD;
         15. Plans to move in the next 3 years&#xD;
&#xD;
         16. A member of the participant's household is currently in the trial&#xD;
&#xD;
         17. Inability or unwillingness of individual or legal guardian /representative to give&#xD;
             written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorairaj Prabhakaran, MD, DM, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Public Health Foundation of India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kavita Singh, MSc.</last_name>
    <phone>+91-11-26850118</phone>
    <phone_ext>39</phone_ext>
    <email>kavita@ccdcindia.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bangalore Endocrinology and Diabetes Research Centre,</name>
      <address>
        <city>#35, 5th Cross,Malleswaram Circle,</city>
        <state>Bangalore, Karnataka</state>
        <zip>560 003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mala Dharmalingam, MD DM</last_name>
      <phone>+919845208163</phone>
      <email>drmala@bedrc.com</email>
    </contact>
    <investigator>
      <last_name>Mala Dharamalingam, MD DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John's Medical College &amp; Hospital,</name>
      <address>
        <city>Sarjapur Road, Koramangala,</city>
        <state>Bangalore</state>
        <zip>560 034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganapathy Bantwal, MD DM</last_name>
      <phone>+919448067318</phone>
      <email>mallyaganapathi@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>Ganapathy Bantwal, MD DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes Research Centre &amp; MV Hospital for Diabetes,</name>
      <address>
        <city>No 4 West Madha Church Street, Royapuram</city>
        <state>Chennai</state>
        <zip>600 013</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Viswanathan, MD DM</last_name>
      <phone>+919840055535</phone>
      <email>dr_vijay@vsnl.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Vishwanatha, MD DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Public Health Foundation of India</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorairaj Prabhakaran, MD, DM, MSc.</last_name>
      <phone>+91-11-26850588</phone>
      <email>dprabhakaran@ccdcindia.org</email>
    </contact>
    <investigator>
      <last_name>Nikhil Tandon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrine Division, Department of Medicine, Goa Medical College,</name>
      <address>
        <city>Bambolim</city>
        <state>Goa</state>
        <zip>403202</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ankush Desai, MD DM</last_name>
      <phone>+91-9923486199</phone>
      <email>ankush_desai@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>Ankush Desai, MD DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology, CARE Hospital,</name>
      <address>
        <city>Road No 1, Banjara Hills,</city>
        <state>Hyderabad,</state>
        <zip>500 034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bipin Sethi, MD, DM</last_name>
      <phone>+919848021482</phone>
      <email>bipinkumarsethi@yahoo.co.uk</email>
    </contact>
    <investigator>
      <last_name>Bipin Sethi, MD, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osmania General Hospital,</name>
      <address>
        <city>2nd Floor, Golden Jubilee Block, Afzalgunj,</city>
        <state>Hyderabad</state>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Sahay, MD DM</last_name>
      <phone>+919849597507</phone>
      <email>sahayrk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Sahay, MD DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A G Unnikrishnan, MD, DM</last_name>
      <phone>+91-4844001559</phone>
      <email>unnikrishnanag@aims.amrita.edu</email>
    </contact>
    <investigator>
      <last_name>A G Unnikrishnan, Md, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Topiwala National Medical College &amp; BYL Nair Ch. Hospital,</name>
      <address>
        <city>Dr. A. L. Nair Road, Mumbai Central,</city>
        <state>Mumbai</state>
        <zip>400 008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Premalata Varthakavi, MD, DM</last_name>
      <phone>+919224480560</phone>
      <email>premavar@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Premlatha Varthakavi, MD, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of CHS, The Aga Khan, University,</name>
      <address>
        <city>P.O. BOx. 3500 Stadium, Road,</city>
        <state>Karachi</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Daudzai, MBBS</last_name>
      <phone>+92214930051</phone>
      <phone_ext>4919</phone_ext>
      <email>hassan.daudzai@aku.edu</email>
    </contact>
    <investigator>
      <last_name>Abdul Jabbar, MD DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>September 6, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>September 2, 2011</last_update_submitted>
  <last_update_submitted_qc>September 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T2DM</keyword>
  <keyword>Decision support software</keyword>
  <keyword>care coordinator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 1, 2019</submitted>
    <returned>August 20, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

